June 2006 in “American Journal of Epidemiology” Higher BMI is linked to a lower risk of non-aggressive prostate cancer and a higher risk of aggressive prostate cancer.
75 citations,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
35 citations,
January 2012 in “The Journal of Sexual Medicine” Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.
1 citations,
July 2017 in “The Journal of Urology” Low-dose finasteride and dutasteride reduce PSA levels by 27.8% in men with male androgenetic alopecia.
March 2024 in “PLoS medicine” Physical activity, height, and smoking affect prostate cancer risk.
37 citations,
April 2008 in “The Cochrane library” 5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
4 citations,
November 2017 in “Cancer Causes & Control” Men who start balding at age 20 may have a higher chance of getting aggressive prostate cancer.
10 citations,
October 2012 in “Andrology” Prostate cancer can progress even with low testosterone due to internal hormone production in the tumor.
218 citations,
December 2011 in “Advances in Urology” The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.
50 citations,
April 2010 in “Biology direct” Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.
32 citations,
May 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
23 citations,
July 1993 in “Pharmacotherapy” Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.
15 citations,
December 2006 in “Clinical interventions in aging” 5 alpha-reductase inhibitors like finasteride may lower prostate cancer risk and improve cancer screening.
14 citations,
November 2008 in “Expert opinion on drug metabolism & toxicology” Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.
9 citations,
July 2018 in “Medicine” Men with vertex baldness may have a higher risk of developing prostate cancer, but more research is needed to confirm this.
1 citations,
July 2022 in “Cancer Epidemiology, Biomarkers & Prevention” 5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.
1 citations,
June 2010 in “Mayo Clinic Proceedings” The conclusion is that individualized treatment and proper medication use are crucial in men's health, with specific recommendations for ED, BPH, and prostate cancer management.
December 2023 in “International Journal of Molecular Sciences” Men with early balding showed higher levels of certain genes linked to hair loss and possibly prostate cancer.
April 2022 in “Authorea (Authorea)” CT scans can find serious prostate cancer even when PSA levels are low.
January 2021 in “HAMDAN MEDICAL JOURNAL” Finasteride treats hair loss and reduces prostate cancer risk.
90 citations,
January 2003 in “The Journal of Urology” Finasteride may reduce prostate bleeding by lowering blood vessel growth factor levels and blood vessel density in certain prostate areas.
10 citations,
June 2010 in “Expert Opinion on Drug Metabolism & Toxicology” Finasteride reduces prostate cancer risk but may increase high-grade cancer chances.
12 citations,
October 2018 in “Aging male/The aging male” Higher BMI and lower testosterone are linked to more aggressive prostate cancer.
August 2019 in “The Journal of Urology” Treatment with 5α-reductase inhibitors is linked to a delay in prostate cancer diagnosis and may affect survival rates.
57 citations,
July 2016 in “The Journal of Sexual Medicine” 5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
April 2015 in “The Journal of Urology” Finasteride reduces PSA levels by around 40-50% in BPH patients.
13 citations,
May 2018 in “Urologic Oncology: Seminars and Original Investigations” Finasteride does not prevent bladder cancer.
77 citations,
May 2012 in “Expert Opinion on Emerging Drugs” New treatments for male hypogonadism are effective and should be personalized.
17 citations,
February 2001 in “Urologia Internationalis” Stopping alpha-blocker medication after 6-9 months is safe and effective for most patients with bladder outlet obstruction.
1 citations,
March 2021 in “Phytomedicine plus” Cernitin™, a pollen extract, was found to significantly reduce pain and inflammation in rats with chronic prostatitis, suggesting it could be a useful alternative to certain anti-inflammatory drugs.